Surrozen, Inc. - Common Stock (SRZN)
Frequently Asked Questions About Surrozen, Inc. - Common Stock (SRZN)
Has Surrozen, Inc. published any research?
Yes, Surrozen, Inc. has contributed to the scientific community through various publications that detail their findings on Wnt signaling and its implications in disease mechanisms and potential therapeutic approaches.
How can I invest in Surrozen, Inc.?
You can invest in Surrozen, Inc. by purchasing shares through a stock brokerage account that offers access to the Nasdaq market, where the company is listed under the ticker symbol 'SRZN'.
Is Surrozen, Inc. publicly traded?
Yes, Surrozen, Inc. is publicly traded on the Nasdaq under the ticker symbol 'SRZN', allowing investors to participate in the company's growth and innovation in biotechnology.
What are Surrozen's key areas of focus?
Surrozen focuses on key areas such as organ regeneration, tissue repair, and specific conditions like liver and kidney diseases, employing its proprietary platform to develop Wnt-targeted therapeutics.
What are the potential benefits of Surrozen's therapies?
The potential benefits of Surrozen's therapies include improved tissue and organ repair, reduced recovery times, and enhanced quality of life for patients suffering from regenerative medicine-related ailments.
What challenges does Surrozen face?
Like many biotech firms, Surrozen faces challenges such as navigating regulatory approvals, securing funding for ongoing research and development, and demonstrating the clinical efficacy of its therapies.
What does Surrozen, Inc. do?
Surrozen, Inc. is a biotechnology company focused on developing innovative therapeutics to selectively modulate Wnt signaling pathways. The company's primary aim is to address unmet medical needs in various diseases, particularly in areas such as organ regeneration and tissue repair.
What is Surrozen's approach to intellectual property?
Surrozen is committed to protecting its innovations through a comprehensive intellectual property strategy, which involves filing patents related to its proprietary technologies, compounds, and therapeutic approaches.
What is Surrozen's mission statement?
Surrozen's mission is to develop transformative therapeutics that harness the power of Wnt biology to enable regenerative medicine, ultimately improving the lives of patients with unmet medical needs.
What is Surrozen's proprietary platform?
Surrozen's proprietary platform is designed to create monoclonal antibodies that can selectively modulate the Wnt signaling pathway. This technology aims to enable the development of novel therapeutics to regenerate damaged tissues.
What is Surrozen's vision for the future?
Surrozen envisions a future where its innovative therapeutics significantly improve patient care by enabling the body to heal itself, thereby transforming treatment paradigms in regenerative medicine.
What is the current status of Surrozen's clinical trials?
Surrozen is actively conducting clinical trials to evaluate the safety and efficacy of its product candidates, with results expected to inform future development and potential marketing of its therapies.
What is the goal of Surrozen's therapies?
The goal of Surrozen's therapies is to improve patient outcomes by enhancing the body's natural regenerative capabilities, thereby promoting recovery and healing in tissues that are diseased or damaged.
What is Wnt signaling?
Wnt signaling is a complex network of proteins involved in regulating cell-to-cell interactions during embryogenesis and plays a crucial role in tissue homeostasis, regeneration, and repair processes.
What partnerships or collaborations has Surrozen established?
Surrozen has sought strategic collaborations with research institutions and other biotechnology companies to enhance its scientific research, broaden its technological capabilities, and expedite the development of its therapeutics.
When was Surrozen, Inc. founded?
Surrozen, Inc. was founded in 2016, with the goal of harnessing the potential of Wnt signaling to develop novel therapeutic options for patients suffering from a variety of conditions.
Where is Surrozen, Inc. headquartered?
Surrozen, Inc. is headquartered in South San Francisco, California, an area known for its vibrant biotech ecosystem and proximity to leading universities and research institutions.
Who are the founders of Surrozen, Inc.?
Surrozen, Inc. was founded by a team of experts in the fields of biology, medicine, and pharmaceutical development, including Dr. Craig C. Ceol, Dr. Sheri P. L. Willingham, and Dr. John R. B. Sweeney.
Who is on Surrozen's executive team?
Surrozen's executive team comprises experienced leaders with backgrounds in biotechnology, pharmaceuticals, and business development, including a mix of clinical, operations, and financial expertise.
What is the current price of Surrozen, Inc. - Common Stock?
The current price of Surrozen, Inc. - Common Stock is 21.72
When was Surrozen, Inc. - Common Stock last traded?
The last trade of Surrozen, Inc. - Common Stock was at 4:00 pm EDT on July 22nd, 2026